A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...

Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

Last week, federal jurors in Delaware awarded Regeneron Pharmaceuticals Inc. more than $400 million in its antitrust showdown with Amgen Inc., the company’s rival in the market for cholesterol ...

A jury found Amgen liable for antitrust violations, awarding Regeneron $406.8 million in damages related to Praluent competition. A federal court jury in Delaware has ruled that Amgen Inc ...

A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen (NASDAQ:AMGN) violated U.S. antitrust laws by forcing pharmacy benefit managers ...

We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more. From STAT’s Andrew Joseph: Lars Fruergaard ...

Last week, federal jurors in Delaware awarded Regeneron Pharmaceuticals Inc. more than $400 million in its antitrust showdown with Amgen Inc., the company’s rival in the market for cholesterol ...

Federal court jury found Amgen liable for violating antitrust ... from competing in the market Jury awarded Regeneron $135.6 million dollars of compensatory damages and $271.2 million dollars ...